Alora completed the acquisition of the legacy business of Osmotica Pharmaceuticals for $170m.

Alora Pharmaceuticals, a pharmaceuticals company, completed the acquisition of the legacy business of Osmotica Pharmaceuticals, a fully integrated biopharmaceutical company, for $170m. “The legacy business has been an important part of our evolution, and we would like to recognize the excellent performance of our employees as they have remained focused throughout this process. The proceeds generated by the sale will be used to retire a substantial portion of our outstanding indebtedness and position us to accelerate the commercialization efforts of our flagship product, UPNEEQ. Since the introduction of UPNEEQ, our confidence in the brand has continued to grow, and we believe that this is the right time to further focus on this tremendous asset," Brian Markison, Osmotica Pharmaceuticals CEO.